Beam, Inc. (BEAM) Tops Q3 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/11/2026
- S&P 500, Dow futures attempt recovery ahead of inflation report
- Oracle raises full year profit guidance, stock rises after hours
- Oil surges 6%, Brent and US crude both surpass $100 on more tanker attacks
- Analysts split on Apple after foldable iPhone Duo debut
- JPMorgan upgrades Meta on AI models and agents, sees 'meaningful headroom'
- White House copper tariff plan stalls amid affordability concerns, sources say
- Micron's Taiwan workers to get rewards worth up to 68 months of pay
- Crude Inventory 0.4M Barrels Last Week - EIA
- Vertiv shares drop on acquisition skepticism, AI pullback
- Copart nears $2B all-cash deal to acquire ACV Auctions - Bloomberg
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
JPMorgan Reiterates Overweight Rating on Beam Therapeutics Inc (BEAM)
November 5, 2024 2:56 PM ESTJPMorgan analyst Eric Joseph reiterated an Overweight rating and $48.00 price target on Beam Therapeutics Inc (NASDAQ: BEAM).
The analyst comments "Key updates alongside 3Q results (loss per share of $1.17) centered on the companys SCD/B-thal cell therapy franchise ahead of multiple presentations at... More
Stifel Defending Beam Therapeutics Inc (BEAM): 'Reactions To Initial BEAM-101 Update Strikes Us As Overreaction'
November 5, 2024 11:47 AM ESTStifel analyst Benjamin Burnett reiterated a Buy rating and $69.00 price target on Beam Therapeutics Inc (NASDAQ: BEAM)
The analyst comments "As expected from an initial update from a lead program, early BEAM-101 (sickle cell disease [SCD]) disclosure offers important takeaways that, understandably, trigger investor... More
BMO Capital on Beam Therapeutics Inc (BEAM): 'We see BEAM-101 clinical data as positive'
November 5, 2024 8:58 AM ESTBMO Capital analyst Kostas Biliouris reiterated an Outperform rating and $57.00 price target on Beam Therapeutics Inc (NASDAQ: BEAM).
The analyst comments "The first-ever clinical data from BEAM's base editing platform in SCD demonstrate a robust BEAM-101 efficacy/safety profile with differentiating characteristics compared... More
